Otezla (Apremilast)

Apremilast, the active ingredient in Otezla, is a phosphodiesterase‑4 (PDE4) inhibitor presented as a tablet for oral use. It modulates immune activity and is indicated for inflammatory skin and joint disorders in adults. GNH USA supplies Otezla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Apremilast is an oral immunomodulator used in several chronic inflammatory conditions. - Plaque psoriasis: reduces the severity and extent of skin lesions. - Psoriatic arthritis: alleviates joint pain, swelling, and improves physical function. - Behçet's disease oral ulcers: promotes healing of recurrent mouth ulcers.

Apremilast is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Headache: transient cranial discomfort. - Upper respiratory tract infection: cold‑like symptoms. - Nasopharyngitis: irritation of the nose and throat. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Depression: new or worsening mood disturbances. - Suicidal ideation: thoughts of self‑harm requiring immediate evaluation. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Pancreatitis: abdominal pain with elevated enzymes. - Severe infections: opportunistic or opportunistic bacterial infections.

Before initiating therapy, clinicians should consider several safety aspects. - Renal function assessment: adjust use in moderate to severe impairment. - Hepatic monitoring: avoid in severe liver disease. - Depression screening: evaluate baseline mood and monitor regularly. - Pregnancy and lactation: use only if potential benefit outweighs risk. - Hypersensitivity: discontinue if allergic reaction occurs. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Apremilast may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase apremilast exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): can raise plasma levels.

Moderate Interactions (Monitor Closely):\n- Warfarin: monitor INR for potential anticoagulant effect changes. - Digoxin: observe for altered serum concentrations. - Other PDE4 inhibitors: increased risk of overlapping side effects.